ClinicalTrials.gg
RecruitingNCT07319845Updated Oct 28, 2026

A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes

A Phase 2 interventional study of TAK-226 in Myelodysplastic Syndromes, sponsored by Takeda. Recruiting at 21 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 28, 2026Site recruiting status changedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Myelodysplastic Syndromes by Takeda — 4 open to participants now, 4 under way, 2 of them phase 3. Myelodysplastic Syndromes · Takeda.

Planned enrollment
8th of 12
42 · median 66
Started
2026
with 1 other
Phase 2
4 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Myelodysplastic Syndromes by Takeda, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 12th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

4 of the 13 studies in Myelodysplastic Syndromes by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Myelodysplastic Syndromes by Takeda, or all of them as a file.
02

Study summary

The main aim of the study is to evaluate how TAK-226 improves symptoms of transfusion-dependent anemia in Japanese patients with lower-risk myelodysplastic syndromes.

The study consists of Screening Period (up to 6 weeks), Treatment Period, Safety Follow-Up Period (8 weeks), and Long-Term Follow-Up Period (approximately 5 years from the first dose of the study treatment).

Participants of this study will be administered TAK-226 during Treatment Period. Subsequently, the participants will be monitored for side effects related to the study treatment during Safety Follow-Up Period and Long-Term Follow-Up Period. The approximate duration of participation for a participant is up to approximately 6 years.

During the study period, participants will visit the study clinic/hospital multiple times as per the study schedule. During Treatment Period, the participants will come to the clinic/hospital approximately every two to four weeks.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • Drug Therapy
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants or their legally authorized representative must be willing and able to sign the ICF and to adhere to the protocol requirements.
  2. Japanese adult male or female participant greater than or equal to (>=) 18 years of age at the time of signing .
  3. Diagnosis of MDS with or without ring sideroblasts (RS) (as determined in an evaluable bone marrow sample collected at screening to confirm diagnosis) according to WHO 2016 classification that meets the International Prognostic Scoring System-Revised (IPSS-R) classification of very low-, low-, or intermediate-risk MDS.

    Note: Due to expected impacts of transfusion, (Hgb) values from blood samples collected within 14 days following a red blood cell (RBC) transfusion and count obtained within 7 days following a platelet transfusion cannot be used for IPSS-R eligibility, unless considered pretransfusion values.

  4. Transfusion dependent (TD) cohort: Transfusion dependence assessed in the 16 weeks immediately preceding enrollment in two 8-week blocks classified as either:

    1. Low-transfusion burden (LTB), defined as 4 to 7 RBC units per 16 weeks; or
    2. High-transfusion burden (HTB), defined as >=8 RBC units per 16 weeks; and
    3. For all participants:

    i. Only transfusion events for a pretransfusion Hgb \<10 grams per deciliter (g/dL) are counted toward eligibility; ii. At least 1 transfusion event in each 8-week block and a minimum of 2 transfusion events separated by >=7 days within the 16-week period immediately preceding enrollment; and iii. No consecutive 56-day period can be RBC transfusion-free during the 16 week period immediately preceding enrollment.

    Note: Only transfusions for the disease under study will be counted towards classification for LTB or HTB participants. Transfusions for intercurrent diseases (bleeding, surgical procedure, infection, etc.) are not considered.

    Non-transfusion dependent (NTD) cohort: NTD, defined as 0 to 1 RBC units per 8 weeks immediately preceding enrollment.

    Note: RBC transfusions administered when Hgb levels were \<9.0 g/dL are counted for eligibility. RBC transfusions administered for other than MDS-related anemia (bleeding, surgical procedure, infection, etc.) will not be counted as a required transfusion for the purpose of meeting eligibility criteria.

  5. TD cohort: or intolerant to prior erythropoiesis-stimulating agent (ESA) treatment (discontinued >=4 weeks before enrollment), or unlikely to respond to ESA treatment, defined as follows:

    a. Refractory to prior ESA treatment: documentation of nonresponse or a response that was no longer maintained with a prior ESA-containing regimen, either as a single agent or combination (eg, with granulocyte colony-stimulating factor [G-CSF]); ESA regimen must have been either: i. Recombinant human erythropoietin (EPO) >=30,000 IU/week for >=8 doses or equivalent; or ii. Darbepoetin alpha >=500 mcrg every 3 weeks for >=3 doses, >=120 mcrg every week for >=8 doses or equivalent.

    b. Intolerant to prior ESA treatment: documentation of discontinuation of a prior ESA containing regimen, either as a single agent or combination (eg, with G-CSF), at any time after introduction due to intolerance or an AE.

    c. Unlikely to respond to ESA treatment: low chance of response to ESA based on an endogenous serum EPO level >200 U/L.

    Note: Due to expected impacts of transfusion on EPO levels, blood samples collected within the 14 days following an RBC transfusion or within 7 days following a platelet transfusion cannot be used to evaluate serum EPO level for eligibility, unless considered pretransfusion values.

    NTD cohort: Hgb \<10 g/dL and exhibiting anemia-related clinical symptoms (eg, fatigue, shortness of breath, or others) during screening.

  6. Less than 5% blasts in an evaluable bone marrow sample collected at screening.
  7. (ECOG) performance status of 0 to 2.
  8. Women of (WOCBP), defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally for at least 12 consecutive months must

    1. Agree to use 1 highly effective method of and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 60 days after the last dose of study drug; or
    2. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
  9. Male participants must, even if he is surgically sterilized (ie, status postvasectomy), a. Agree to practice effective barrier contraception the time of signing the informed consent through 60 days after the last dose of study drug; or Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)

Exclusion criteria

Exclusion Criteria:

Medical History

  1. Del(5q) MDS or secondary MDS.
  2. Anemia due to any other known cause (eg, thalassemia, hemolytic anemia, bleeding events, or deficiency of iron, B12, and/or folate).
  3. Receipt of RBC transfusion for any reason(s) other than underlying MDS within 16 weeks in TD cohort or 8 weeks in NTD cohort before enrollment.
  4. cardiovascular disease defined as:

    1. heart disease class III or IV;
    2. Fridericia (QTcF) interval >500 milliseconds during screening;
    3. Presence of uncontrolled hypertension defined as mean systolic blood pressure >=160 mm Hg or diastolic blood pressure >=100 mm Hg during screening; or
    4. Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before screening.
  5. Known \<35%, confirmed by a local echocardiogram performed during screening, or a previously performed echocardiogram if collected within 6 months before screening.
  6. Stroke, deep vein thrombosis, or pulmonary embolism within 6 months before screening.
  7. Any known history of acute myeloid leukemia (AML).
  8. Prior history of , other than MDS, unless the participant has been free of the disease (including completion of any treatment, including maintenance, for prior malignancy) for >=2 years. However, participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy:

    1. Basal or squamous cell carcinoma of the skin;
    2. Carcinoma in situ of the cervix;
    3. Carcinoma in situ of the breast; and/or
    4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, [TNM] clinical staging system).
    5. Early papillary thyroid cancer (stage I [T1-T2, N0, M0]).
  9. History of solid organ or bone marrow transplantation.
  10. Active infection requiring intravenous antibiotics within 28 days or oral antibiotics within 14 days before enrollment.
  11. Active infection with , active infectious virus (HBV), or active infectious virus (HCV). Participants who are positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis B surface antibody (HBsAb) may be eligible for enrollment if their hepatitis B viral load is below the limit of detection. Participants who are positive for hepatitis C virus antibodies (HCVAb) may be enrolled if their hepatitis C viral load is below the limit of detection.
  12. >=40 kg/m\^2.
  13. Major surgery within 28 days before enrollment.
  14. History of allergy/anaphylaxis to medicinal product (IMP) (refer to the current elritercept [TAK 226] IB for a list of excipients) or recombinant proteins.

    Treatment History

  15. TD cohort: Prior use of TAK 226, luspatercept, imetelstat, or sotatercept. NTD cohort: Prior use of TAK 226, luspatercept, imetelstat, sotatercept, or ESAs.

    Note for NTD cohort: At the investigator's discretion in consultation with the medical monitor, may be allowed if received no more than 2 doses of ESAs >=8 weeks prior to enrollment.

  16. Prior use of hypomethylating agents (HMAs), isocitrate dehydrogenase inhibitor, lenalidomide, or therapy given for treatment of MDS.
  17. Iron chelation therapy initiated within 8 weeks before enrollment. Participants on stable or decreasing doses of iron chelation therapy for >=8 weeks are allowed.
  18. Vitamin B12 or folate therapy initiated within 4 weeks before enrollment. Participants on stable replacement doses for >=4 weeks and without ongoing concurrent vitamin B12 or folate deficiency are allowed.
  19. Androgen use within 8 weeks before enrollment. Participants on stable androgen dosing for hypogonadism for >=8 weeks are allowed.
  20. High-dose systemic use within 4 weeks before enrollment. Participants on stable chronic steroid doses of prednisone/prednisolone \<=10 mg/day or corticosteroid equivalent for >=4 weeks are allowed.
  21. Treatment with any investigational drug within 28 days before screening or, if the half-life of the product is known, within 5 times the half-life before screening, whichever is longer.
  22. Ongoing participation in another interventional clinical study.

    Laboratory Exclusions (during Screening)

  23. Serum EPO level >500 U/L. Note: Due to expected impacts of transfusion on EPO levels, laboratory results from blood samples collected within the 14 days following an RBC transfusion cannot be used to evaluate serum EPO level for eligibility, unless considered pretransfusion values.
  24. count >=800*10\^3/mcrL or \<=25*10\^3/mcrL. Note: Due to expected impacts of transfusion, laboratory results from blood samples collected within the 7 days following a platelet transfusion cannot be used to evaluate platelet count for eligibility, unless they are considered pretransfusion values.
  25. \<=500/mcrL
  26. Serum or ALT >=3*the (ULN).
  27. Total >=2*ULN. Participants with known history of Gilbert syndrome with unconjugated bilirubin \<3*ULN are allowed.
  28. Ferritin \<=50 mcrg/L.
  29. Folate \<=2.0 ng/mL.
  30. Vitamin B12 \<=200 pg/mL.
  31. Estimated \<30 mL/min/1.73 m\^2 as determined by Japanese Society of Nephrology. Calculated by the correction formula for Japanese. a)

    a) eGFR=194* (serum creatinine value)\^-1.094* (age)\^-0.287* (sex correction factor), Sex correction factor: 0.739 in female.

    Miscellaneous

  32. Pregnant or lactating female. Note: Participants who may be in the very early stage of pregnancy based on the doctor's interview with a negative pregnancy test are excluded from the study. Participants who are lactating will be eligible if they discontinue breastfeeding from before the first dose of study drug until 60 days after the last dose of study drug.
  33. Any other condition not specifically noted above that, in the opinion of the investigator, would preclude the participant from participating in the study or could confound interpretation of data from the study.

Investigational site staff members directly involved in the conduct of the study and site staff members otherwise supervised by the investigator, employees of the Sponsor or contract research organization (CRO) directly involved in the conduct of the study, or immediate family members (defined as a spouse, parent, child, or sibling, whether biological or legally adopted).

Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    TAK-226

    Participants will receive the study drug, TAK-226, administered subcutaneously every four weeks (Q4W) for approximately one year during Treatment Period.

    Drug: TAK-226

Interventions

  • TAK-226 subcutaneous injection

    Also known as: Elritercept, KER-050

06

What researchers measure

Primary outcomes

  1. Transfusion dependent (TD) cohort: Percentage of Participants Achieving Transfusion Independence (TI) for Greater Than or Equal to (>=) 8 Weeks from Baseline through Week 24

    Transfusion independence is defined as the absence of any red blood cells (RBC) transfusions in a period of at least 8 weeks after the first dose of the study treatment through week 24.

    Time frame: Baseline, Up to Week 24

  2. Non-transfusion dependent (NTD) cohort: Percentage of Participants Achieving Mean Hgb Increase of >=1.5 grams per deciliter (g/dL) for >=8 Weeks from Baseline through Week 24 And No RBC Transfusion during the Same >=8 Weeks Period

    Time frame: Baseline, Up to Week 24

Secondary outcomes

  1. TD cohort: Percentage of Participants Achieving TI for >=24 Weeks from Baseline through Week 48

    Transfusion independence is defined as the absence of any red blood cells (RBC) transfusions in a period of at least 24 weeks after the first dose of the study treatment through week 48.

    Time frame: Baseline, Up to Week 48

  2. TD cohort: Percentage of Participants with High Transfusion Burden (HTB) Achieving TI for >=8 Weeks from Baseline through Week 24

    Transfusion independence is defined as the absence of any RBC transfusions in a period of at least 8 weeks after the first dose of the study treatment through week 24.

    Time frame: Baseline, Up to Week 24

  3. TD cohort: Percentage of Participants Achieving Mean Hemoglobin (Hgb) Increase of >=1.5 g/dL for >=8 Weeks from Baseline through Week 24

    Time frame: Baseline, Up to Week 24

  4. TD cohort: Number of Participants with Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Event (SAEs)

    An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the trial intervention, whether or not the occurrence is considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the trial intervention. A TEAE is defined as an AE that commences on or after the first dose of the study treatment and within 60 days after the last dose of the study treatment, or analysis cutoff date, whichever is earlier. An SAE is any untoward medical occurrence that, at any dose: results in death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.

    Time frame: Up to approximately 6 years

  5. TD cohort: Serum Concentration of TAK-226

    TAK-226 time-concentration data will be assessed.

    Time frame: Baseline, and multiple time points up to the end of Treatment Period (approximately 12 months)

  6. TD cohort: Number of Participants with Treatment-Emergent Anti-Drug Antibody (ADA)

    Time frame: Up to the end of Safety Follow-Up Period (approximately 14 months)

  7. TD cohort: ADA Titer

    Time frame: Baseline, and multiple time points up to approximately 24 months

  8. NTD cohort: Percentage of Participants Achieving Mean Hgb Increase of >=1.5 g/dL for >=12 Weeks from Baseline through Week 24 And No RBC Transfusion during the Same >=12 Weeks Period

    Time frame: Baseline, Up to Week 24

  9. NTD cohort: Percentage of Participants Achieving Consecutive Hgb Increase of >=1.5 g/dL for >=8 Weeks from Baseline through Week 24 And No RBC Transfusion during the Same >=8 Weeks Period

    Time frame: Baseline, Up to Week 24

  10. NTD cohort: Percentage of Participants Achieving Mean Hgb Increase of >=1.5 g/dL for >=16 Weeks from Baseline through Week 24 And through Week 48, And No RBC Transfusion during the Same >=16 Weeks Period

    Time frame: Baseline, Up to Week 24 and Week 48

  11. NTD cohort: Number of Participants with TEAEs and SAEs

    Time frame: Up to approximately 6 years

  12. TD and NTD cohorts: Change from baseline in Hematocrit

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  13. TD and NTD cohorts: Change from baseline in Hemoglobin

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  14. TD and NTD cohorts: Change from baseline in Red Cell Distribution Width

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  15. TD and NTD cohorts: Change from baseline in Red Blood Cell

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  16. TD and NTD cohorts: Change from baseline in Reticulocyte

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  17. TD and NTD cohorts: Change from baseline in Platelet

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  18. TD and NTD cohorts: Change from baseline in White Blood Cell

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  19. TD and NTD cohorts: Change from baseline in Neutrophils

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  20. TD and NTD cohorts: Change from baseline in Eosinophils

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  21. TD and NTD cohorts: Change from baseline in Basophils

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  22. TD and NTD cohorts: Change from baseline in Lymphocytes

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  23. TD and NTD cohorts: Change from baseline in Monocytes

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  24. TD and NTD cohorts: Change from baseline in Mean Corpuscular Volume

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  25. TD and NTD cohorts: Change from baseline in Mean Corpuscular Hemoglobin

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  26. TD and NTD cohorts: Change from baseline in Mean Cell Hemoglobin Concentration

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  27. TD and NTD cohorts: Change from baseline in Albumin

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  28. TD and NTD cohorts: Change from baseline in Total Protein

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  29. TD and NTD cohorts: Change from baseline in Blood Glucose

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  30. TD and NTD cohorts: Change from baseline in Sodium

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  31. TD and NTD cohorts: Change from baseline in Potassium

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  32. TD and NTD cohorts: Change from baseline in Chloride

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  33. TD and NTD cohorts: Change from baseline in Blood Urea Nitrogen

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  34. TD and NTD cohorts: Change from baseline in Creatinine

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  35. TD and NTD cohorts: Change from baseline in Aspartate Aminotransferase

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  36. TD and NTD cohorts: Change from baseline in Alanine Aminotransferase

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  37. TD and NTD cohorts: Change from baseline in Alkaline Phosphatase

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  38. TD and NTD cohorts: Change from baseline in Gamma Glutamyl Transferase

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  39. TD and NTD cohorts: Change from baseline in Total Bilirubin

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  40. TD and NTD cohorts: Change from baseline in Lactate Dehydrogenase

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  41. TD and NTD cohorts: Change from baseline in Calcium

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  42. TD and NTD cohorts: Change from baseline in Magnesium

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  43. TD and NTD cohorts: Change from baseline in Phosphorus

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  44. TD and NTD cohorts: Change from baseline in Uric Acid

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  45. TD and NTD cohorts: Change from baseline in Erythropoietin

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  46. TD and NTD cohorts: Change from baseline in Thrombopoietin

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  47. TD and NTD cohorts: Change from baseline in N-Terminal Prohormone of Brain Natriuretic Protein

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  48. TD and NTD cohorts: Change from baseline in Serum Iron

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  49. TD and NTD cohorts: Change from baseline in Ferritin

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  50. TD and NTD cohorts: Change from baseline in Transferrin

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  51. TD and NTD cohorts: Change from baseline in Transferrin Saturation

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  52. TD and NTD cohorts: Change from baseline in Total Iron Binding Capacity

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  53. TD and NTD cohorts: Change from baseline in Soluble Transferrin Receptor

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  54. TD and NTD cohorts: Change from baseline in Hepcidin

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  55. TD and NTD cohorts: Change from baseline in Blood Pressure

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  56. TD and NTD cohorts: Change from baseline in Heart Rate

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  57. TD and NTD cohorts: Change from baseline in Respiratory Rate

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  58. TD and NTD cohorts: Change from baseline in Body Temperature

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  59. TD and NTD cohorts: Change from baseline in PR Interval

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  60. TD and NTD cohorts: Change from baseline in QRS Duration

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  61. TD and NTD cohorts: Change from baseline in QT Interval

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

  62. TD and NTD cohorts: Change from baseline in QTcF Interval

    Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months

07

Study locations

11 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 26 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 6, 2026
StartActual
Apr 22, 2026
Primary completionEst.
Jun 26, 2028
CompletionEst.
Jan 10, 2033
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Kindai University Hospital · Osaka, JapanNot yet recruiting→Recruiting
  • Tokyo Metropolitan Komagome Hospital · Tokyo, JapanNot yet recruiting→Recruiting
  • Yamagata University Hospital · Yamagata, JapanNot yet recruiting→Recruiting
Show site
  • Yamagata University Hospital · Yamagata, Japan
across 2 updates, Oct 6, 2026 – Oct 28, 2026
Eligibility
11 inclusion criteria edited, 2 added, 2 removed; 12 exclusion criteria edited, 2 added
What changed in the criteria
Inclusion criteria
  • EditedJapanese adult male or female participant greater than or equal to (>=) 18 years of age at the time of signing informed consent.
  • EditedDiagnosis of MDS with or without ring sideroblasts (RS) (as determined in an evaluable bone marrow aspiratesample collected at Screeningscreening to confirm diagnosis) according to WHO 2016 classification that meets the International Prognostic Scoring System-Revised (IPSS-R) classification of very low-, low-, or intermediate-risk MDS.
  • EditedNote: Due to expected impacts of transfusion, hemoglobin (Hgb) values from blood samples collected within 14 days following a red blood cell (RBC) transfusion and platelet count obtained within 7 days following a platelet transfusion cannot be used to evaluatefor IPSS-R for eligibilityeligibility, unless considered pretransfusion values.
  • EditedTransfusion dependent (TD[YY1.1]) cohort: Transfusion dependence assessed in the 16 weeks immediately preceding enrollment in two 8-week blocks classified as either:
  • EditedHigh-transfusion burden (HTB[YY2.1]), defined as >=8 RBC units per 16 weeks; and
  • AddedFor all participants:
  • EditedFor all participants: i. Only transfusion events for a pretransfusion Hgb <10 grams per deciliter (g/dL) are counted toward eligibility; ii. At least 1 transfusion event in each 8-week block and a minimum of 2 transfusion events separated by >=7 days within the 16-week period immediately preceding enrollment; and iii. No consecutive 56-day period can be RBC transfusion-free during the 16 week period immediately preceding enrollment.
  • EditedNon-transfusion dependent (NTD[YY3.1]) cohort: NTD, defined as 0 to 1 RBC units per 8 weeks immediately preceding enrollment.
  • EditedRefractory to prior ESA treatment: documentation of nonresponse or a response that was no longer maintained with a prior ESA-containing regimen, either as a single agent or combination (eg, with granulocyte colony-stimulating factor [G-CSF]); ESA regimen must have been either: i. Recombinant human erythropoietin (EPO) >=4030,000 IU/week for >=8 doses or equivalent; or ii. Darbepoetin alpha >=500 mcrg every 3 weeks for >=43 doses, >=120 mcrg every week for >=8 doses or equivalent. b. Intolerant to prior ESA treatment: documentation of discontinuation of a prior ESA containing regimen, either as a single agent or combination (eg, with G-CSF), at any time after introduction due to intolerance or an AE.
  • AddedIntolerant to prior ESA treatment: documentation of discontinuation of a prior ESA containing regimen, either as a single agent or combination (eg, with G-CSF), at any time after introduction due to intolerance or an AE.
  • EditedNote: Due to expected impacts of transfusion on EPO levels, blood samples collected within the 14 days following an RBC transfusion or within 7 days following a platelet transfusion cannot be used to evaluate serum EPO level for eligibility, unless considered pretransfusion values.
  • EditedLess than 5% blasts in an evaluable bone marrow aspiratesample collected at Screeningscreening.
  • RemovedMale participants must, even if he is surgically sterilized (ie, status postvasectomy),
  • RemovedAgree to practice effective barrier contraception the time of signing the informed consent through 60 days after the last dose of study drug; or
  • EditedMale participants must, even if he is surgically sterilized (ie, status postvasectomy), a. Agree to practice effective barrier contraception the time of signing the informed consent through 60 days after the last dose of study drug; or Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
Exclusion criteria
  • EditedDel(5q) MDS or therapy-related (secondary) MDS.
  • EditedPrior history of malignancies, other than MDS, unless the participant has been free of the disease (including completion of any treatment, including maintenance, for prior malignancy) for >=52 years. However, participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy:
  • AddedEarly papillary thyroid cancer (stage I [T1-T2, N0, M0]).
  • EditedHistory of or known active or chronicActive infection with HIV, active infectious hepatitis B virus (HBV), or active infectious hepatitis C virus (HCV). Participants who are positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis B surface antibody (HBsAb) may be eligible for enrollment if their hepatitis B viral load is below the limit of detection. Participants who are positive for hepatitis C virus antibodies (HCVAb) may be enrolled if their hepatitis C viral load is below the limit of detection.
  • EditedTD cohort: Prior use of TAK 226, luspatercept, imetelstat, or sotatercept. [YY4.1] NTD cohort: Prior use of TAK 226, luspatercept, imetelstat, sotatercept, or ESAs.
  • EditedIron chelation therapy initiated within 8 weeks before enrollment. Participants on stable or decreasing doses of iron chelation therapy for >=8 weeks are allowed.
  • EditedHigh-dose systemic corticosteroid use within 4 weeks before enrollment. Participants on stable chronic steroid doses of prednisone/prednisolone <=10 mg/day or corticosteroid equivalent for >=4 weeks are allowed.
  • EditedOngoing participation in another interventional clinical study. Laboratory Exclusions (during Screening)
  • AddedLaboratory Exclusions (during Screening)
  • EditedSerum EPO level >500 U/L. Note: Due to expected impacts of transfusion on EPO levels, laboratory results from blood samples collected within the 14 days following an RBC transfusion cannot be used to evaluate serum EPO level for eligibility, unless considered pretransfusion values.
  • EditedPlatelet count >=450800*10\^3/mcrL or <=25*10\^3/mcrL. Note: Due to expected impacts of transfusion, laboratory results from blood samples collected within the 7 days following a platelet transfusion cannot be used to evaluate platelet count for eligibility, unless they are considered pretransfusion values.
  • EditedTotal bilirubin >=2*ULN unless attributable to. Participants with known history of Gilbert syndrome with unconjugated bilirubin <3*ULN are allowed.
  • EditedEstimated glomerular filtration rate <30 mL/min/1.73m73 m\^2 as determined by Japanese Society of Nephrology. Calculated by the correction formula for Japanese. a)
  • EditedPregnant or lactating female[YY5.1]. Note: Participants who may be in the very early stage of pregnancy based on the doctor's interview with a negative pregnancy test are excluded from the study. Participants who are lactating will be eligible if they discontinue breastfeeding from before the first dose of study drug until 60 days after the last dose of study drug.
Oct 13, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedTD and NTD cohorts: Change from baseline in Reticulocyte Cell HemoglobinTime frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
Oct 13, 2026
Show all 3 updates
  1. Oct 28, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Tokyo Metropolitan Komagome Hospital · Tokyo, JapanNot yet recruiting→Recruiting
    • Yamagata University Hospital · Yamagata, JapanNot yet recruiting→Recruiting
    + 1 other change: oversight details
  2. Oct 13, 2026
    Eligibility 11 inclusion criteria edited, 2 added, 2 removed; 12 exclusion criteria edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • EditedJapanese adult male or female participant greater than or equal to (>=) 18 years of age at the time of signing informed consent.
    • EditedDiagnosis of MDS with or without ring sideroblasts (RS) (as determined in an evaluable bone marrow aspiratesample collected at Screeningscreening to confirm diagnosis) according to WHO 2016 classification that meets the International Prognostic Scoring System-Revised (IPSS-R) classification of very low-, low-, or intermediate-risk MDS.
    • EditedNote: Due to expected impacts of transfusion, hemoglobin (Hgb) values from blood samples collected within 14 days following a red blood cell (RBC) transfusion and platelet count obtained within 7 days following a platelet transfusion cannot be used to evaluatefor IPSS-R for eligibilityeligibility, unless considered pretransfusion values.
    • EditedTransfusion dependent (TD[YY1.1]) cohort: Transfusion dependence assessed in the 16 weeks immediately preceding enrollment in two 8-week blocks classified as either:
    • EditedHigh-transfusion burden (HTB[YY2.1]), defined as >=8 RBC units per 16 weeks; and
    • AddedFor all participants:
    • EditedFor all participants: i. Only transfusion events for a pretransfusion Hgb <10 grams per deciliter (g/dL) are counted toward eligibility; ii. At least 1 transfusion event in each 8-week block and a minimum of 2 transfusion events separated by >=7 days within the 16-week period immediately preceding enrollment; and iii. No consecutive 56-day period can be RBC transfusion-free during the 16 week period immediately preceding enrollment.
    • EditedNon-transfusion dependent (NTD[YY3.1]) cohort: NTD, defined as 0 to 1 RBC units per 8 weeks immediately preceding enrollment.
    • EditedRefractory to prior ESA treatment: documentation of nonresponse or a response that was no longer maintained with a prior ESA-containing regimen, either as a single agent or combination (eg, with granulocyte colony-stimulating factor [G-CSF]); ESA regimen must have been either: i. Recombinant human erythropoietin (EPO) >=4030,000 IU/week for >=8 doses or equivalent; or ii. Darbepoetin alpha >=500 mcrg every 3 weeks for >=43 doses, >=120 mcrg every week for >=8 doses or equivalent. b. Intolerant to prior ESA treatment: documentation of discontinuation of a prior ESA containing regimen, either as a single agent or combination (eg, with G-CSF), at any time after introduction due to intolerance or an AE.
    • AddedIntolerant to prior ESA treatment: documentation of discontinuation of a prior ESA containing regimen, either as a single agent or combination (eg, with G-CSF), at any time after introduction due to intolerance or an AE.
    • EditedNote: Due to expected impacts of transfusion on EPO levels, blood samples collected within the 14 days following an RBC transfusion or within 7 days following a platelet transfusion cannot be used to evaluate serum EPO level for eligibility, unless considered pretransfusion values.
    • EditedLess than 5% blasts in an evaluable bone marrow aspiratesample collected at Screeningscreening.
    • RemovedMale participants must, even if he is surgically sterilized (ie, status postvasectomy),
    • RemovedAgree to practice effective barrier contraception the time of signing the informed consent through 60 days after the last dose of study drug; or
    • EditedMale participants must, even if he is surgically sterilized (ie, status postvasectomy), a. Agree to practice effective barrier contraception the time of signing the informed consent through 60 days after the last dose of study drug; or Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
    Exclusion criteria
    • EditedDel(5q) MDS or therapy-related (secondary) MDS.
    • EditedPrior history of malignancies, other than MDS, unless the participant has been free of the disease (including completion of any treatment, including maintenance, for prior malignancy) for >=52 years. However, participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy:
    • AddedEarly papillary thyroid cancer (stage I [T1-T2, N0, M0]).
    • EditedHistory of or known active or chronicActive infection with HIV, active infectious hepatitis B virus (HBV), or active infectious hepatitis C virus (HCV). Participants who are positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis B surface antibody (HBsAb) may be eligible for enrollment if their hepatitis B viral load is below the limit of detection. Participants who are positive for hepatitis C virus antibodies (HCVAb) may be enrolled if their hepatitis C viral load is below the limit of detection.
    • EditedTD cohort: Prior use of TAK 226, luspatercept, imetelstat, or sotatercept. [YY4.1] NTD cohort: Prior use of TAK 226, luspatercept, imetelstat, sotatercept, or ESAs.
    • EditedIron chelation therapy initiated within 8 weeks before enrollment. Participants on stable or decreasing doses of iron chelation therapy for >=8 weeks are allowed.
    • EditedHigh-dose systemic corticosteroid use within 4 weeks before enrollment. Participants on stable chronic steroid doses of prednisone/prednisolone <=10 mg/day or corticosteroid equivalent for >=4 weeks are allowed.
    • EditedOngoing participation in another interventional clinical study. Laboratory Exclusions (during Screening)
    • AddedLaboratory Exclusions (during Screening)
    • EditedSerum EPO level >500 U/L. Note: Due to expected impacts of transfusion on EPO levels, laboratory results from blood samples collected within the 14 days following an RBC transfusion cannot be used to evaluate serum EPO level for eligibility, unless considered pretransfusion values.
    • EditedPlatelet count >=450800*10\^3/mcrL or <=25*10\^3/mcrL. Note: Due to expected impacts of transfusion, laboratory results from blood samples collected within the 7 days following a platelet transfusion cannot be used to evaluate platelet count for eligibility, unless they are considered pretransfusion values.
    • EditedTotal bilirubin >=2*ULN unless attributable to. Participants with known history of Gilbert syndrome with unconjugated bilirubin <3*ULN are allowed.
    • EditedEstimated glomerular filtration rate <30 mL/min/1.73m73 m\^2 as determined by Japanese Society of Nephrology. Calculated by the correction formula for Japanese. a)
    • EditedPregnant or lactating female[YY5.1]. Note: Participants who may be in the very early stage of pregnancy based on the doctor's interview with a negative pregnancy test are excluded from the study. Participants who are lactating will be eligible if they discontinue breastfeeding from before the first dose of study drug until 60 days after the last dose of study drug.
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedTD and NTD cohorts: Change from baseline in Reticulocyte Cell HemoglobinTime frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
    + 2 other changes: oversight details and description
  3. Oct 6, 2026
    1 site added. Kindai University Hospital is now Recruiting
    Show site
    • Yamagata University Hospital · Yamagata, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07319845
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Apr 22, 2026
Primary completion
Jun 26, 2028 (estimated)
Completion
Jan 10, 2033 (estimated)
Last update
Oct 28, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elritercept

Start the discussion